208 related articles for article (PubMed ID: 11161452)
1. Fas/Apo-1 (CD95)-mediated apoptosis of neutrophils with Fas ligand (CD95L)-expressing tumors is crucial for induction of inflammation by neutrophilic polymorphonuclear leukocytes associated with antitumor immunity.
Shimizu M; Fontana A; Takeda Y; Yoshimoto T; Tsubura A; Matsuzawa A
Cell Immunol; 2001 Jan; 207(1):41-8. PubMed ID: 11161452
[TBL] [Abstract][Full Text] [Related]
2. Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells.
Shimizu M; Fontana A; Takeda Y; Yagita H; Yoshimoto T; Matsuzawa A
J Immunol; 1999 Jun; 162(12):7350-7. PubMed ID: 10358186
[TBL] [Abstract][Full Text] [Related]
3. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively.
Hashimoto W; Osaki T; Okamura H; Robbins PD; Kurimoto M; Nagata S; Lotze MT; Tahara H
J Immunol; 1999 Jul; 163(2):583-9. PubMed ID: 10395644
[TBL] [Abstract][Full Text] [Related]
4. Mice deficient in fas ligand (gld) or fas (lpr) show few alterations in granulopoiesis.
Fecho K; Bentley SA; Cohen PL
Cell Immunol; 1998 Aug; 188(1):19-32. PubMed ID: 9743554
[TBL] [Abstract][Full Text] [Related]
5. Castration induces apoptosis in the male accessory sex organs of Fas-deficient lpr and Fas ligand-deficient gld mutant mice.
Sugihara A; Yamada N; Tsujimura T; Iwasaki T; Yamashita K; Takagi Y; Tsuji M; Terada N
In Vivo; 2001; 15(5):385-90. PubMed ID: 11695234
[TBL] [Abstract][Full Text] [Related]
6. A trial to kill tumor cells through Fas (CD95)-mediated apoptosis in vivo.
Shimizu M; Yoshimoto T; Nagata S; Matsuzawa A
Biochem Biophys Res Commun; 1996 Nov; 228(2):375-9. PubMed ID: 8920922
[TBL] [Abstract][Full Text] [Related]
7. Immunological and pathological consequences of mutations in both Fas and Fas ligand.
Weintraub JP; Godfrey V; Wolthusen PA; Cheek RL; Eisenberg RA; Cohen PL
Cell Immunol; 1998 May; 186(1):8-17. PubMed ID: 9637760
[TBL] [Abstract][Full Text] [Related]
8. Modification of tumor cells with Fas (CD95) antigen gene and Fas ligand (CD95L) gene transfection by electroporation for immunotherapy of cancer.
Shimizu M; Yoshimoto T; Matsuzawa A; Takeda Y
Mol Biotechnol; 2003 Sep; 25(1):79-87. PubMed ID: 13679638
[TBL] [Abstract][Full Text] [Related]
9. Defective Fas ligand-mediated apoptosis predisposes to development of a chronic erosive arthritis subsequent to Mycoplasma pulmonis infection.
Hsu HC; Zhang HG; Song GG; Xie J; Liu D; Yang PA; Fleck M; Wintersberger W; Zhou T; Edwards CK; Mountz JD
Arthritis Rheum; 2001 Sep; 44(9):2146-59. PubMed ID: 11592380
[TBL] [Abstract][Full Text] [Related]
10. Fas system-mediated apoptosis suppresses lymphopoiesis.
Yasutomo K; Nagasawa H; Hisaeda H; Good RA; Kuroda Y; Himeno K
J Immunol; 1996 Sep; 157(5):1981-6. PubMed ID: 8757318
[TBL] [Abstract][Full Text] [Related]
11. Ultraviolet light-induced immune tolerance is mediated via the Fas/Fas-ligand system.
Schwarz A; Grabbe S; Grosse-Heitmeyer K; Roters B; Riemann H; Luger TA; Trinchieri G; Schwarz T
J Immunol; 1998 May; 160(9):4262-70. PubMed ID: 9574528
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis abnormalities of splenic lymphocytes in autoimmune lpr and gld mice.
Reap EA; Leslie D; Abrahams M; Eisenberg RA; Cohen PL
J Immunol; 1995 Jan; 154(2):936-43. PubMed ID: 7529292
[TBL] [Abstract][Full Text] [Related]
13. Fas-mediated apoptosis is involved in the elimination of gene-transduced hepatocytes with E1/E3-deleted adenoviral vectors.
Okuyama T; Li XK; Funeshima N; Fujino M; Sasaki K; Kita Y; Kosuga M; Takahashi M; Saito H; Suzuki S; Yamada M
J Gastroenterol Hepatol; 1998 Sep; 13 Suppl():S113-8. PubMed ID: 9792044
[TBL] [Abstract][Full Text] [Related]
14. Ca2+-dependent, Fas- and perforin-independent apoptotic death of allografted tumor cells by a type of activated macrophage.
Yoshida R; Sanchez-Bueno A; Yamamoto N; Einaga-Naito K
J Immunol; 1997 Jul; 159(1):15-21. PubMed ID: 9200433
[TBL] [Abstract][Full Text] [Related]
15. Chemotactic activity of soluble Fas ligand against phagocytes.
Seino K; Iwabuchi K; Kayagaki N; Miyata R; Nagaoka I; Matsuzawa A; Fukao K; Yagita H; Okumura K
J Immunol; 1998 Nov; 161(9):4484-8. PubMed ID: 9794371
[TBL] [Abstract][Full Text] [Related]
16. Treatment of chronic sialadenitis in a murine model of Sjögren's syndrome by local fasL gene transfer.
Fleck M; Zhang HG; Kern ER; Hsu HC; Müller-Ladner U; Mountz JD
Arthritis Rheum; 2001 Apr; 44(4):964-73. PubMed ID: 11315936
[TBL] [Abstract][Full Text] [Related]
17. Fas- and FasL-deficient mice are resistant to induction of autoimmune encephalomyelitis.
Waldner H; Sobel RA; Howard E; Kuchroo VK
J Immunol; 1997 Oct; 159(7):3100-3. PubMed ID: 9317104
[TBL] [Abstract][Full Text] [Related]
18. T cell dependent and independent antitumor immunity generated by the expression of Fas ligand on mouse lung carcinoma cells.
Tada Y; O-Wang J; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
Int J Mol Med; 2002 Mar; 9(3):281-5. PubMed ID: 11836634
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effect of allogenic fibroblasts engineered to express Fas ligand (FasL).
Drozdzik M; Qian C; Lasarte JJ; Bilbao R; Prieto J
Gene Ther; 1998 Dec; 5(12):1622-30. PubMed ID: 10023441
[TBL] [Abstract][Full Text] [Related]
20. Different susceptibility of cytotoxic T cells to CD95 (Fas/Apo-1) ligand-mediated cell death after activation in vitro versus in vivo.
Ehl S; Hoffmann-Rohrer U; Nagata S; Hengartner H; Zinkernagel R
J Immunol; 1996 Apr; 156(7):2357-60. PubMed ID: 8786290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
